Costs of inflammatory bowel disease in the Netherlands: the COIN study

In Chapter 2 we describe the prevalence of work disability in IBD patients. In this study, we compared the work disability rates of IBD patients with the general Dutch population. Furthermore, we assessed the predictive factors for work disability. Chapter 3 focuses on IBD-related costs and identification of major cost drivers in IBD patients in the anti-TNF era. Chapter 4 describes the evolution of IBD-related costs over two years of follow-up and identifies predictors of future IBD-related costs. Chapter 5 reports on the effect of different treatment modalities in UC patients on UC-related costs and qualityof- life. Chapter 6 describes the analysis of cost-effectiveness of remission-induction with anti-TNF compounds versus corticosteroid-based therapy in CD using two-year follow-up data. In Chapter 7 the benefit of immunomodulators in anti-TNF therapy is assessed, which is based on a large, nationwide registry database from “Apotheekzorg”, including all CD patients receiving adalimumab between 2004-2010. In Chapter 8 the results are summarized and discussed and suggestions for further research is given. A Dutch summary is presented in Chapter 9.